Promotional Implications of Proprietary Prescription Drug Names

Data to Support Drug Product Communications

⚠️ Notice: This information collection may be referencing outdated material. More recent filings for OMB 0910-0695 can be found here:

Documents and Forms

Document Name Document Type
Pretest Questionnaire.docx Other-Survey Instrument
Proprietary Name Consent Form.docx Other-Informed Consent
0695 OMB Approval Memo - Pro Implications of PP Drug Names 2019.docx OMB Approval Memo IC Document

Information Collection (IC) Details

IC Title:	Promotional Implications of Proprietary Prescription Drug Names	Agency IC Tracking Number:	CDER

IC Status: New

Obligation to Respond: Voluntary

CFR Citation:

Information Collection Instruments:

Document Type	Form No.	Form Name	Instrument File	URL	Available Electronically?	Can Be Submitted Electronically?	Electronic Capability
Other-Survey Instrument			Pretest Questionnaire.docx		Yes	Yes	Fillable Fileable
Other-Informed Consent			Proprietary Name Consent Form.docx		Yes	Yes	Fillable Fileable

Line of Business: Health

Subfunction: Consumer Health and Safety

Privacy Act System of Records
Title:	FR Citation:

Number of Respondents: 2,460	Number of Respondents for Small Entity: 0

Affected Public: Individuals or Households

Percentage of Respondents Reporting Electronically: 100 %

	Approved	Program Change Due to Agency Discretion
Annual Number of Responses for this IC	2,460	2,460
Annual IC Time Burden (Hours)	276	276
Annual IC Cost Burden (Dollars)	0	0

Documents for IC

Title	Document	Date Uploaded
OMB Approval Memo	0695 OMB Approval Memo - Pro Implications of PP Drug Names 2019.docx	07/02/2019

Blank fields in records indicate information that was not collected or not collected electronically prior to July 2006.